Her2抗体与MMAE偶联物的制备及生物活性研究

doi:10.13523/j.cb.20150210

中国生物工程杂志

2015, Vol. 35

Issue (2): 66-71 DOI: 10.13523/j.cb.20150210

技术与方法

Her2抗体与MMAE偶联物的制备及生物活性研究

佘栋宇, 黄嘉慧, 刘东晨, 张途, 谢秋玲

暨南大学生命科学技术学院广东省生物工程药物重点实验室基因工程药物国家工程研究中心广州 510632

Preparation and Biological Activity of Anti-Her2 Antibody-MMAE Conjugate

SHE Dong-yu, HUANG Jia-hui, LIU Dong-chen, ZHANG Tu, XIE Qiu-ling

College of Life Science and Technology, Guangdong Provincial Key Laboratory of Bioengineering Medicine, National Engineering Research Center of Genetic Medicine, Jinan University, Guangzhou 510632, China

全文: PDF(1085 KB) HTML

摘要：

目的:制备Her2抗体与海兔毒素MMAE的偶联物,检测该抗体-药物偶联药物(ADC)对于乳腺癌细胞的抑制作用。方法:将Her2抗体通过一个可降解的linker与小分子毒素(MMAE)连接起来,形成抗体药物偶联物(ADC)。通过细胞学试验检测Her2抗体-MMAE偶联物对于肿瘤细胞抑制、细胞凋亡和细胞周期的作用。结果:通过优化偶联条件,ADC偶联率达80%以上。肿瘤细胞生长抑制的实验显示ADC药物的IC₅₀比单克隆抗体的IC₅₀明显降低,作用效果更加明显。细胞凋亡和细胞周期实验结果表明,ADC药物72h诱导细胞凋亡率高达40%,单一抗体药物则仅为20%。结论:该ADC药物具有很好的抑制乳腺癌细胞的作用。

关键词： Her2抗体; MMAE; 偶联; ADC; 制备

Abstract:

Object: To prepare an antibody drug conjugate (ADC) with Her2 antibody and MMAE. And to test the effect of this ADC on growth, apoptosis and cell cycle of breast cancer cell. Method: Anti-Her2 monoclonal antibody PH was conjugated with MMAE by a linker. The effect of ADC on tumor cell was compared with Her2 antibody in vitro. Results: The conjugating rate was about 80% under the optimized condition. It was shown that this ADC has higher ability than Her2 antibody for inhibiting growth of breast cancer cells, whether with high Her2 expression or low Her2 expression. And this ADC could induced cell apoptosis up to 40 percents, while PH only to 20 percents. Conclusion: The anti-Her2 antibody-MMAE conjugate has higher activity to inhibit cancer cell than Her2 antibody.

Key words: Anti-Her2 antibody MMAE Conjugate ADC Preparation

收稿日期: 2014-12-15 出版日期: 2015-02-25

ZTFLH:

Q819

基金资助:

国家"十二五"重大新药创制项目(2012ZX09202-301-001)、广东省战略性新兴产业核心技术攻关(2012A080800008)资助项目

通讯作者: 谢秋玲 E-mail: txql@jnu.edu.cn

	服务
	把本文推荐给朋友
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

引用本文:

佘栋宇, 黄嘉慧, 刘东晨, 张途, 谢秋玲. Her2抗体与MMAE偶联物的制备及生物活性研究[J]. 中国生物工程杂志, 2015, 35(2): 66-71.

SHE Dong-yu, HUANG Jia-hui, LIU Dong-chen, ZHANG Tu, XIE Qiu-ling. Preparation and Biological Activity of Anti-Her2 Antibody-MMAE Conjugate. China Biotechnology, 2015, 35(2): 66-71.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.20150210 或 https://manu60.magtech.com.cn/biotech/CN/Y2015/V35/I2/66

[1] Carter P J. Introduction to current and future protein therapeutics: a protein engineering perspective. Experimental Cell Research, 2011, 317(9): 1261-1269.

[2] Scott A M, Wolchok J D, Old L J. Antibody therapy of cancer. Nature Reviews Cancer, 2012, 12(4): 278-287.

[3] Sapra P, Hooper A T, O'Donnell C J, et al. Investigational antibody drugconjugates for solid tumors. Expert Opinion on Investigational Drugs, 2011, 20(8): 1131-1149.

[4] Junttila T T, Li G, Parsons K, et al. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Research and Treatment, 2011, 128(2): 347-356.

[5] Wu A M, Senter P D. Arming antibodies: prospects and challenges for immunoconjugates. Nature Biotechnology, 2005, 23(9): 1137-1146.

[6] Bradley A M, Devine M, DeRemer D. Brentuximab vedotin: An anti-CD30 antibody-drug conjugate. American Journal of Health-System Pharmacy, 2013, 70(7): 589-597.

[7] Gerber H P, Koehn F E, Abraham R T. The antibody-drug conjugate: an enabling modality fornatural product-based cancer therapeutics.Natural Product Reports, 2013, 30(5): 625-639.

[8] Sun M M C, Beam K S, Cerveny C G, et al. Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjugate Chemistry, 2005, 16(5): 1282-1290.

[9] Wagner-Rousset E, Janin-Bussat M C, Colas O, et al. Antibody-drug conjugate model fast characterization by LC-MS following IdeS proteolytic digestion
[C]//MAbs. Landes Bioscience, 2014, 6(1): 173.

[10] Zein N, Poncin M, Nilakantan R, et al. Calicheamicin gamma 1I and DNA: molecular recognition process responsible for site-specificity. Science, 1989, 244(4905): 697-699.

[11] Hamblett K J, Senter P D, Chace D F, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clinical Cancer Research, 2004, 10(20): 7063-7070.

[12] Mandelbaum-Shavit F, Wolpert-DeFilippes M K, Johns D G. Binding of maytansine to rat brain tubulin. Biochemical and Biophysical Research Communications, 1976, 72(1): 47-54.

[13] Sapra P, Hooper A T, O'Donnell C J, et al. Investigational antibody drug conjugates for solid tumors. Expert Opinion on Investigational Drugs, 2011, 20(8): 1131-1149.

[1]	陈文洁,苗先锋. 抗体偶联药物国内研发现状及企业布局分析[J]. 中国生物工程杂志, 2021, 41(6): 105-110.
[2]	肖云喜,张俊河,杨雯雯,程洪伟. 用于疫苗生产的人二倍体细胞研究进展^*[J]. 中国生物工程杂志, 2021, 41(11): 74-81.
[3]	杨威,宋方祥,王帅,张黎,王红霞,李焱. 药物输送系统中Janus纳米粒子的制备及应用 ^*[J]. 中国生物工程杂志, 2020, 40(7): 70-81.
[4]	陈春琳,秦松,宋宛霖,刘志丹,刘正一. 褐藻寡糖生物法制备研究进展 ^*[J]. 中国生物工程杂志, 2020, 40(10): 85-95.
[5]	许嘉越,李紫倩,张革. 登革病毒3'UTRΔ30系列疫苗的研究进展[J]. 中国生物工程杂志, 2019, 39(3): 97-104.
[6]	徐欢,周美玲,葛琳,王志明. 人血清白蛋白在蛋白多肽类药物长效化中的应用 ^*[J]. 中国生物工程杂志, 2019, 39(1): 82-89.
[7]	张莉,丁涓,郝宇晨,叶城,蒲洋. 一株海洋微藻的鉴定及其原生质体制备条件优化 ^*[J]. 中国生物工程杂志, 2018, 38(11): 42-50.
[8]	张杨玲,汪园,张革. 埃博拉病毒疫苗rVSV-ZEBOV的研究进展[J]. 中国生物工程杂志, 2018, 38(1): 51-56.
[9]	胡可越, 程宁辉, 王新泉. 人类Grx3蛋白与转录因子p65相互作用的研究[J]. 中国生物工程杂志, 2017, 37(9): 1-6.
[10]	迟胜男,李增兰,张纯,殷爽,冯翠,王祺,刘永东,苏志国. 聚乙二醇20k修饰与转铁蛋白偶联睫状神经营养因子的生物活性对比研究 ^*[J]. 中国生物工程杂志, 2017, 37(12): 59-66.
[11]	王佃亮. 讲座细胞药物的制备工艺——细胞药物连载之二[J]. 中国生物工程杂志, 2016, 36(7): 127-133.
[12]	殷爽, 冯翠, 张纯, 王祺, 王健, 余蓉, 刘永东, 苏志国. 转铁蛋白-PEG-睫状神经营养因子的制备及其生物活性评价[J]. 中国生物工程杂志, 2016, 36(4): 43-49.
[13]	钱建瑛, 许正宏, 窦文芳. 融合蛋白GGH粉针剂制备工艺研究[J]. 中国生物工程杂志, 2016, 36(11): 48-53.
[14]	王兰, 夏懋, 高凯. 抗体偶联药物的研究进展与质量控制[J]. 中国生物工程杂志, 2014, 34(4): 85-94.
[15]	康跻耀, 张宁, 周炜清, 孙李靖, 张贵锋, 马光辉, 苏志国. 基于魔芋葡甘聚糖微球的胶原覆层型微载体的制备研究[J]. 中国生物工程杂志, 2013, 33(5): 44-49.

Viewed

Full text

Abstract

Cited

Shared

Discussed